Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Darinaparsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Solasia Pharma
- 28 Mar 2016 Based on the results of this trial, Solasia intends to file for registration in Japan, South Korea, Taiwan and Hong Kong according to a company media release.
- 01 Mar 2016 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov.
- 01 Mar 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov.